+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Middle East & Africa Human Papillomavirus Vaccine Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Type, Dosage, Age, Application, and End User- Product Image
Middle East & Africa Human Papillomavirus Vaccine Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Type, Dosage, Age, Application, and End User- Product Image
Sale

Middle East & Africa Human Papillomavirus Vaccine Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Type, Dosage, Age, Application, and End User

  • PDF Icon

    Report

  • 150 Pages
  • September 2022
  • Region: Africa, Middle East
  • The Insight Partners
  • ID: 5668506
UP TO OFF until Jun 30th 2024
Description Jump to:
The MEA human papillomavirus (HPV) vaccine market is expected to grow from US$ 82.91 million in 2022 to US$ 100.86 million by 2028; it is estimated to grow at a CAGR of 3.3% from 2022 to 2028.

Healthcare organizations have developed and adopted several strategies to prevent and eliminate HPV infections. The World Health Assembly, in August 2020, adopted the strategy for cervical cancer elimination. As per the strategy, to eliminate cervical cancer, all countries across the region must reach and maintain an incidence rate of below four per 100,000 women. To reduce the incidence rate of cervical cancer, countries should focus on vaccination, screening, and treatment of cervical cancer. In 2016, Gavi Board initiated an HPV vaccine program. That allows countries in their first year of the program to scale up and vaccinate girls between the age of 9 and 14 years. Through this new strategy, Gavi aimed to protect about 40 million girls from cervical cancer by 2020, preventing an estimated 900,000 deaths. Many countries accepted the Gavi support and introduced the HPV vaccine in their national immunization program. Countries with the highest burden of cervical cancer, initiated the Gavi HPV vaccine program. All these initiatives are aiding the HPV vaccines market substantially across the region.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the MEA human papillomavirus (HPV) vaccine market . The MEA human papillomavirus (HPV) vaccine market is expected to grow at a good CAGR during the forecast period.

MEA Human Papillomavirus (HPV) Vaccine Market Segmentation

The MEA human papillomavirus (HPV) vaccine market is segmented based on type, dosage, age, application, end user, and country.
  • Based on type, the MEA human papillomavirus (HPV) vaccine market is segmented into 9-valent HPV vaccine, quadrivalent HPV vaccine, and bivalent HPV vaccine. The quadrivalent HPV vaccine segment dominated the market in 2022.
  • Based on dosage, the MEA human papillomavirus (HPV) vaccine market is bifurcated into 2 dose and 3 dose. The 2 dose segment dominated the market in 2022.
  • Based on age, the MEA human papillomavirus (HPV) vaccine market is bifurcated into 9 to 14 years and 15 to 45 years. The 9 to 14 years segment dominated the market in 2022.
  • Based on application, the MEA human papillomavirus (HPV) vaccine market is bifurcated into HPV-attributable cancer and genital warts. The HPV-attributable cancer segment dominated the market in 2022.
  • Based on end user, the MEA human papillomavirus (HPV) vaccine market is segmented into doctors office, community health clinics, school-based health centers, health departments, hospitals, and others. The hospitals segment dominated the market in 2022.
  • Based on country, the MEA human papillomavirus (HPV) vaccine market has been categorized into Saudi Arabia, South Africa, the UAE, Iran, Turkey, Kuwait, Bahrain, Egypt, and the Rest of MEA. Saudi Arabia would dominate the market in 2022.
GlaxoSmithKline plc.; Inovio Pharmaceuticals; Merck & Co., Inc.; R-Pharm; Sanofi; Serum Institute of India Pvt. Ltd; and Walvax Biotechnology Co., Ltd. are among the leading companies in the MEA human papillomavirus (HPV) vaccine market.

Table of Contents

1. Introduction
1.1 Study Scope
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 MEA Human Papillomavirus (HPV) Vaccines Market - By Type
1.3.2 MEA Human Papillomavirus (HPV) Vaccines Market - By Dosage
1.3.3 MEA Human Papillomavirus (HPV) Vaccines Market - By Age
1.3.4 MEA Human Papillomavirus (HPV) Vaccines Market - By Application
1.3.5 MEA Human Papillomavirus (HPV) Vaccines Market - By Distribution Channel
1.3.6 MEA Human Papillomavirus (HPV) Vaccines Market - By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. MEA Human Papillomavirus (HPV) Vaccine Market - Market Landscape
4.1 Overview
4.2 MEA PEST Analysis
4.3 Experts Opinion
5. MEA Human Papillomavirus (HPV) Vaccine Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Increase in Prevalence of HPV Associated Diseases
5.1.2 Initiatives Taken by Health Organizations
5.2 Market Restraints
5.2.1 High Cost of HPV Vaccines
5.3 Future Trends
5.3.1 Advancements in HPV Diagnostics Tests
5.4 Impact Analysis
6. Human Papillomavirus (HPV) Vaccine Market- MEA Analysis
6.1 MEA Human Papillomavirus (HPV) Vaccine Market Revenue Forecast and Analysis
7. MEA Human Papillomavirus (HPV) Vaccine Market Analysis - By Type
7.1 Overview
7.2 By Type: Market Revenue and Forecast Analysis (US$ Million)
7.3 9-valent HPV vaccine
7.3.1 Overview
7.3.2 9-valent HPV vaccine Market Revenue and Forecast to 2028 (US$ Million)
7.4 Quadrivalent HPV vaccine
7.4.1 Overview
7.4.2 Quadrivalent HPV vaccine Market Revenue and Forecast to 2028 (US$ Million)
7.5 Bivalent HPV Vaccine
7.5.1 Overview
7.5.2 Bivalent HPV Vaccine Market Revenue and Forecast to 2028 (US$ Million)
8. MEA Human Papillomavirus (HPV) Vaccine Market Analysis - By Dosage
8.1 MEA Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Dosage (2022 and 2028)
8.2 2 Dose
8.2.1 Overview
8.2.2 2 Dose: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US$ Million)
8.3 3 Dose
8.3.1 Overview
8.3.2 3 Dose: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US$ Million)
9. MEA Human Papillomavirus (HPV) Vaccine Market Analysis - By Age
9.1 MEA Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Age (2022 and 2028)
9.2 9 to 14 Years
9.2.1 Overview
9.2.2 9 to 14 Years: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US$ Million)
9.3 to 45 Years
9.3.1 Overview
9.3.2 to 45 Years: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US$ Million)
10. MEA Human Papillomavirus (HPV) Vaccine Market Analysis - By Application
10.1 MEA Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Application (2022 and 2028)
10.2 HPV-attributable Cancer
10.2.1 Overview
10.2.2 HPV-attributable Cancer: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US$ Million)
10.3 Genital Warts
10.3.1 Overview
10.3.2 Genital Warts: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US$ Million)
11. MEA Human Papillomavirus (HPV) Vaccine Market Analysis - By End User
11.1 Overview
11.2 MEA Human Papillomavirus (HPV) Vaccine Market Revenue Share, by End User (2022 and 2028)
11.3 Doctor Office
11.3.1 Overview
11.3.2 Doctor Office Market Revenue and Forecast to 2028 (US$ Million)
11.4 Community Health Clinics
11.4.1 Overview
11.4.2 Community Health Clinics Market Revenue and Forecast to 2028 (US$ Million)
11.5 School-based Health Centers
11.5.1 Overview
11.5.2 School-based Health Centers Market Revenue and Forecast to 2028 (US$ Million)
11.6 Health Departments
11.6.1 Overview
11.6.2 Health Departments Market Revenue and Forecast to 2028 (US$ Million)
11.7 Hospitals
11.7.1 Overview
11.7.2 Hospitals Market Revenue and Forecast to 2028 (US$ Million)
11.8 Others
11.8.1 Overview
11.8.2 Others Market Revenue and Forecast to 2028 (US$ Million)
12. MEA Human Papillomavirus (HPV) Vaccine Market - Country Analysis
12.1 Overview
12.1.1 MEA: Human Papillomavirus (HPV) Vaccine Market, by Country, 2022 & 2028 (%)
12.1.1.1 UAE: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)
12.1.1.1.1 Overview
12.1.1.1.2 UAE: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US$ Million)
12.1.1.1.3 UAE: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019-2028 (US$ Million)
12.1.1.1.4 UAE: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019-2028 (US$ Million)
12.1.1.1.5 UAE: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019-2028 (US$ Million)
12.1.1.1.6 UAE: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019-2028 (US$ Million)
12.1.1.1.7 UAE: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019-2028 (US$ Million)
12.1.1.2 Saudi Arabia: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)
12.1.1.2.1 Overview
12.1.1.2.2 Saudi Arabia: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US$ Million)
12.1.1.2.3 Saudi Arabia: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019-2028 (US$ Million)
12.1.1.2.4 Saudi Arabia: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019-2028 (US$ Million)
12.1.1.2.5 Saudi Arabia: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019-2028 (US$ Million)
12.1.1.2.6 Saudi Arabia: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019-2028 (US$ Million)
12.1.1.2.7 Saudi Arabia: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019-2028 (US$ Million)
12.1.1.3 South Africa: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)
12.1.1.3.1 Overview
12.1.1.3.2 South Africa: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US$ Million)
12.1.1.3.3 South Africa: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019-2028 (US$ Million)
12.1.1.3.4 South Africa: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019-2028 (US$ Million)
12.1.1.3.5 South Africa: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019-2028 (US$ Million)
12.1.1.3.6 South Africa: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019-2028 (US$ Million)
12.1.1.3.7 South Africa: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019-2028 (US$ Million)
12.1.1.4 Iran: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)
12.1.1.4.1 Overview
12.1.1.4.2 Iran: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US$ Million)
12.1.1.4.3 Iran: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019-2028 (US$ Million)
12.1.1.4.4 Iran: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019-2028 (US$ Million)
12.1.1.4.5 Iran: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019-2028 (US$ Million)
12.1.1.4.6 Iran: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019-2028 (US$ Million)
12.1.1.4.7 Iran: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019-2028 (US$ Million)
12.1.1.5 Turkey: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)
12.1.1.5.1 Overview
12.1.1.5.2 Turkey: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US$ Million)
12.1.1.5.3 Turkey: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019-2028 (US$ Million)
12.1.1.5.4 Turkey: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019-2028 (US$ Million)
12.1.1.5.5 Turkey: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019-2028 (US$ Million)
12.1.1.5.6 Turkey: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019-2028 (US$ Million)
12.1.1.5.7 Turkey: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019-2028 (US$ Million)
12.1.1.6 Kuwait: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)
12.1.1.6.1 Overview
12.1.1.6.2 Kuwait: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US$ Million)
12.1.1.6.3 Kuwait: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019-2028 (US$ Million)
12.1.1.6.4 Kuwait: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019-2028 (US$ Million)
12.1.1.6.5 Kuwait: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019-2028 (US$ Million)
12.1.1.6.6 Kuwait: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019-2028 (US$ Million)
12.1.1.6.7 Kuwait: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019-2028 (US$ Million)
12.1.1.7 Bahrain: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)
12.1.1.7.1 Overview
12.1.1.7.2 Bahrain: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US$ Million)
12.1.1.7.3 Bahrain: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019-2028 (US$ Million)
12.1.1.7.4 Bahrain: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019-2028 (US$ Million)
12.1.1.7.5 Bahrain: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019-2028 (US$ Million)
12.1.1.7.6 Bahrain: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019-2028 (US$ Million)
12.1.1.7.7 Bahrain: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019-2028 (US$ Million)
12.1.1.8 Egypt: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)
12.1.1.8.1 Overview
12.1.1.8.2 Egypt: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US$ Million)
12.1.1.8.3 Egypt: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019-2028 (US$ Million)
12.1.1.8.4 Egypt: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019-2028 (US$ Million)
12.1.1.8.5 Egypt: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019-2028 (US$ Million)
12.1.1.8.6 Egypt: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019-2028 (US$ Million)
12.1.1.8.7 Egypt: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019-2028 (US$ Million)
12.1.1.9 Rest of Middle the East and Africa: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)
12.1.1.9.1 Overview
12.1.1.9.2 Rest of MEA: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US$ Million)
12.1.1.9.3 Rest of MEA: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019-2028 (US$ Million)
12.1.1.9.4 Rest of MEA: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019-2028 (US$ Million)
12.1.1.9.5 Rest of MEA: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019-2028 (US$ Million)
12.1.1.9.6 Rest of MEA: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019-2028 (US$ Million)
12.1.1.9.7 Rest of MEA: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019-2028 (US$ Million)
13. Industry Landscape
13.1 Overview
13.2 Inorganic Growth Strategies
13.2.1 Overview
13.3 Organic Growth Strategies
13.3.1 Overview
14. Company Profiles
14.1 Merck & Co., Inc.
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 GlaxoSmithKline plc.
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Serum Institute of India Pvt. Ltd
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Walvax Biotechnology Co., Ltd.
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Inovio Pharmaceuticals
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Sanofi
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 R-Pharm
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
15. Appendix
15.1 About the Publisher
15.2 Glossary of Terms

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • GlaxoSmithKline plc.
  • Inovio Pharmaceuticals
  • Merck & Co., Inc.
  • R-Pharm
  • Sanofi
  • Serum Institute of India Pvt. Ltd
  • Walvax Biotechnology Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages150
PublishedSeptember 2022
Forecast Period2022 - 2028
Estimated Market Value ( USD ) in 2022 $ 82.91 Million
Forecasted Market Value ( USD ) by 2028 $ 100.86 Million
Compound Annual Growth Rate3.3%
Regions CoveredAfrica, Middle East

Related Topics

Related Reports

Human Papillomavirus Vaccine - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Human Papillomavirus Vaccine - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 140 Pages
  • Global
From
Human Papillomavirus Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Valence, By Disease Indication, By Distribution Channel, By Region, and By Competition - Product Image

Human Papillomavirus Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Valence, By Disease Indication, By Distribution Channel, By Region, and By Competition

  • Report
  • 116 Pages
  • Global
From
Global Human Papillomavirus Vaccine Market by Disease Indication (Anal Cancer, Cervical Cancer, Genital Warts), Type (Bivalent, Tetravalent & Nonavalent), Distribution Channel - Forecast 2024-2030 - Product Image

Global Human Papillomavirus Vaccine Market by Disease Indication (Anal Cancer, Cervical Cancer, Genital Warts), Type (Bivalent, Tetravalent & Nonavalent), Distribution Channel - Forecast 2024-2030

  • Report
  • 189 Pages
  • Global
From
COVID-19 Vaccine Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, and Product Type - Product Image

COVID-19 Vaccine Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, and Product Type

  • Report
  • 101 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.